- Pharmaceutical company Tryp Therapeutics is developing a proprietary synthetic hallucinogen as potential medical solutions for select unmet health needs, with a focus on taking psychedelic therapeutics beyond mental health
- The company recently attended the Wonderland: Miami where Compass Pathways unveiled highly anticipated data from their Phase 2b trial in treatment-resistant depression
- Tryp’s Chairman and CEO Greg McKee served on a panel at Wonderland: Miami discussing the potential of synthetic psilocybin in chronic pain indications and the importance of supporting industry wins
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) Chairman and CEO Greg McKee recently participated in Microdose’s Wonderland: Miami conference as a panelist for the “Developing Psychedelic Medicine Beyond What We Already Know” forum exploring the potential of once-taboo substances that are gaining an increasing measure of legitimacy and legal recognition.
McKee’s appearance at the Nov. 8 and 9 event billed as “The Largest Psychedelic Medicine Business Event, Ever” gave Tryp an audience that was expected to include participants from a span of up to 140 countries or more in the Sun Belt’s “Magic City,” a world-class hub for trade and tourism. Greg gave an overview of Tryp’s strategy and progress, as well as addressing the crowd in a call to action to continue to emphasize strong support from every angle in order to give psychedelic therapeutic potential the validation it has already proven to deserve.
The Compass data provided proof of rapid and durable responses after three weeks of psilocybin dosing and psychotherapy. Tryp has been actively engaged in developing synthetic psychedelic drugs as the newest sought-after solutions in treating chronic pain and other medical conditions with largely unmet needs. These data continue to validate Tryp’s hypothesis, as Tryp continues to progress towards conducting 4 Phase 2a trials evaluating psilocybin and psychotherapy in fibromyalgia, and eating disorder, pending a favorable review by the FDA.
The company’s submission of an Investigational New Drug application to the U.S. Food and Drug Administration (“FDA”) for its TRP-8802 clinical candidate (https://ibn.fm/mz1Je) marks the latest advancement in its clinical trial that will initially evaluate 25mg oral psilocybin drug candidate, provided by Usona Institute. Compass Pathway’s data revealed the highest response rate among the 25mg dosing cohort, which provides further support for Tryp’s upcoming trial, and Tryp’s trademarked drug candidate, TRP-8803. TRP-8803 will be a synthetic psilocybin drug candidate in which the Company is completing preclinical and bridging studies to perfect its novel route of administration that will lead to more precise control over the patient’s psychedelic experience during the treatment.
Tryp expects to complete a Phase 2a trial for TRP-8802 during the next nine months to determine its safety and initial effectiveness among patients with fibromyalgia. Similarly, TRP-8802 will be evaluated for its performance in treating phantom limb pain and complex regional pain syndrome (“CRPS”). Additional testing in select eating disorders is expected soon pending further review from the FDA.
The clinical trials will be run in combination with psychotherapists trained by Fluence Training.
The company has developed a novel method of administering TRP-8803 to make the experience better for patients. Although testing is still in the pre-clinical stage for it, Tryp expects to benefit from data produced in the TRP-8802 trials as well as data derived directly from TRP-8803 to advance it to phase 2b testing within the next 18 months and on to eventual commercialization. Tryp is committed to driving clinical progress and doing its part to continue to validate the use of psilocybin in select chronic diseases.
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
